Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials.
about
Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific RegionTranslational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care.Reviews of individual patient data (IPD) are useful for geriatrics: an overview of available IPD reviews.Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology.Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease.The Item-Specific Deficit Approach to evaluating verbal memory dysfunction: rationale, psychometrics, and applicationSafety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's diseaseCholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trialsPopulation pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease.Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging.Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance.Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer's disease.The safety and tolerability of donepezil in patients with Alzheimer's disease.Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.Donepezil in Alzheimer's disease: From conventional trials to pharmacogeneticsThe effects of galantamine treatment on attention and its relationship with cognition and activities of daily living in patients with mild to moderate Alzheimer's disease.Depressive symptoms are associated with analgesic use in people with Alzheimer's disease: Kuopio ALSOVA study.Cognitive Improvement during Treatment for Mild Alzheimer's Disease with a Chinese Herbal Formula: A Randomized Controlled TrialSymptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes.Clinical trials in mild cognitive impairment: lessons for the future.Alzheimer's disease: the benefits of early treatment.Clinical aspects of inflammation in Alzheimer's disease.100 years and counting: prospects for defeating Alzheimer's diseaseGlobal assessment measures for assessing efficacy in dementia drug trials.Randomized controlled trials for schizophrenia: study designs targeted to distinct goals.Progress update: Pharmacological treatment of Alzheimer's disease.Aspects of beta-amyloid as a biomarker for Alzheimer's disease.Cholinesterase inhibitors: beyond Alzheimer’s disease.Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease.Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.Association between Anti-Dementia Treatment Persistence and Daily Dosage of the First Prescription: A Retrospective Analysis in Neuropsychiatric Practices in Germany.Efficacy and safety of donepezil in patients with Alzheimer's disease in assisted living facilities.Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series.Successful intervention to mitigate an acetylcholinesterase inhibitor-induced rhinorrhea prescribing cascade: a case report.Donepezil is associated with decreased in-hospital mortality as a result of pneumonia among older patients with dementia: A retrospective cohort study.
P2860
Q28067006-F191F4EC-C11D-4686-900B-A70B390D9500Q30407039-C051782E-E690-437A-87FF-6E2AF7E2D96BQ30443975-0E44C0DA-D2C6-48FD-B47B-A1CAA025E279Q30815345-F0AE8CAC-A4D1-44F3-B38B-5635D2026EBBQ30998627-FE6E1CED-E14B-426D-B1A4-1B7549769196Q33586027-01F245F5-8CBE-4873-88FD-EEA090A16CCCQ33888160-C1185B77-BFBA-4A2B-8CCF-9B11BA00A1BAQ33911859-1B7307EF-E675-47EB-8455-B617B45BD995Q33912750-1EAAE61D-4365-4485-B792-CA45D5B489E8Q34014237-04556FDE-F127-4F4E-8C47-604746541B04Q34209573-CD96DB9A-3EC8-4568-B067-8B2B84D7D162Q34297733-63233D64-4CD1-4C55-B3E7-70F072CDA7F6Q34402925-9E43995D-63A2-4CC0-B381-D600D43D5B39Q34463351-7C863B63-CF26-4AB1-8C78-9226A36394ADQ34549155-92C935C2-FC28-47F2-81FD-1A94F65BCB5BQ34552035-0E3FE49C-A3D5-4790-834C-379481CE69DBQ34746698-F66314FA-7163-4A5E-A476-A78AE9241FA6Q34762064-18525224-4A63-44FD-8B8E-721F1B1B734DQ34965949-D97F65E3-D96E-41F7-9E7E-BCF5B78B0036Q34996548-828A8E9B-E5A1-40F2-A8AD-93AE9A5B6541Q35092449-6F0783A3-6B64-4EAF-99DF-A64C30CF8BF8Q35663934-9B4AEA86-4F7E-4B0E-86F5-955BE3D3B83FQ35765716-43E43D2B-7B5F-4004-88DA-0BA2D167AE6FQ35876403-CFB6E9FE-2F69-43FB-A969-9646AA305005Q36142255-CBFF5207-6BBD-4505-8078-24657A95663EQ36249975-1E32F7FA-E85A-4145-A7F3-C2B8E0F76B2FQ36364213-D0217E73-A657-4E3F-B103-2A3A8E9C22ECQ36643419-16D8785D-D7FC-4B70-93B7-B0197897D349Q36806629-90B18572-85E2-4B38-99A9-46504AB7D248Q37075598-CF959BA5-48F6-405B-B3A9-760B2AA23BCCQ37129735-A128FCAA-7F3C-4907-AF25-60D77355114AQ37755129-23BA4950-B1B6-49AF-923B-3230E147FF82Q37806711-930A6A7A-4F9B-4C44-878C-CF6DC77FC686Q39340473-0D70BB9C-8154-4062-967C-ACA1CBA63459Q40195274-EE4F3CF4-0B08-4854-A673-7748A7985CAEQ40260505-8723DCCA-85E4-48E3-9F1F-86B84A834905Q43013986-4D9D11CD-42CF-46FC-A3A7-8E58C8764F8AQ46947275-185756F6-8A52-48CA-AD98-E71CACE56A8CQ47324182-A204C3C3-98D2-4892-B9A7-8EA4CBE6BB61Q47594415-4573B044-1237-4E04-9C1C-EA6A47D22742
P2860
Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Donepezil for the symptomatic ...... randomised controlled trials.
@ast
Donepezil for the symptomatic ...... randomised controlled trials.
@en
type
label
Donepezil for the symptomatic ...... randomised controlled trials.
@ast
Donepezil for the symptomatic ...... randomised controlled trials.
@en
prefLabel
Donepezil for the symptomatic ...... randomised controlled trials.
@ast
Donepezil for the symptomatic ...... randomised controlled trials.
@en
P2093
P356
P1476
Donepezil for the symptomatic ...... randomised controlled trials.
@en
P2093
Anne Whitehead
Carlos Perdomo
Gordon K Wilcock
Jacqueline Birks
John Grimley Evans
Raymond D Pratt
P304
P356
10.1002/GPS.1133
P407
P577
2004-07-01T00:00:00Z